Oculis went public via a SPAC merger with European Biotech Acquisition in a $220m deal.

Oculis, a developer of novel and transformative topical treatments, went public via a SPAC merger with European Biotech Acquisition in a $220m deal. Investors in PIPE indue Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, Tekla Capital Management and VI Partners. “EBAC and its investors are exceptionally pleased with the closing of this business combination with Oculis. We value the advanced-stage, diversity and novelty of Oculis’ assets and we are confident in the expertise and experience of Oculis’ leadership team, Board of Directors, Scientific Advisory Board and network of world-class industry collaborators to bring tremendous value to the advancement of treatment outcomes in ophthalmology. We are excited about the potential of Oculis’ differentiated pipeline to meet medical needs for patients," Eduardo Bravo, EBAC CEO.